This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

By Sage Swaby · Inc.com · 10/26/2026

A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.

Full credit and content belongs to Sage Swaby and Inc.com. This page links to their original work — we never republish it.